India, Feb. 24 -- Medtronic plc (MDT), healthcare technology firm, announced Monday the U.S. Food and Drug Administration (FDA) approval of BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI).
Deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain.
DBS uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Medtronic has now enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology, introducing...